Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Clinical Excellence. 2002. (Record no. 11039)

MARC details
000 -LEADER
fixed length control field 00732cam a2200241 4500
001 - CONTROL NUMBER
control field A020941
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 090401t2002 xxu||||| |||| 00| 0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1842571583
035 ## - SYSTEM CONTROL NUMBER
System control number (Sirsi) i9781842571583
060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number WE 346.
110 ## - MAIN ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Nice
245 ## - TITLE STATEMENT
Title Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. National Institute for Clinical Excellence. 2002.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Name of publisher, distributor, etc. NICE,
Date of publication, distribution, etc. 2002
300 ## - PHYSICAL DESCRIPTION
Extent 22p
500 ## - GENERAL NOTE
General note Technology Appraisal Guidance No. 36.
591 ## -
-- P
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Arthritis, rheumatoid
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Drug therapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Clinical effectiveness
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Evidence based practice
710 ## - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element National Inst Clinical Excellence
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC Do not Suppress in OPAC

No items available.

London Health Libraries Koha Consortium privacy notice